These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 22419576)

  • 1. Marked upregulation of Survivin and Aurora-B kinase is associated with disease progression in the myelodysplastic syndromes.
    Yoshida A; Zokumasu K; Wano Y; Yamauchi T; Imamura S; Takagi K; Kishi S; Urasaki Y; Tohyama K; Ueda T
    Haematologica; 2012 Sep; 97(9):1372-9. PubMed ID: 22419576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aurora-B expression may not contribute to disease progression: a reflection of the heterogeneous pathogenesis?
    Heredia FF; de Sousa JC; Carvalho AF; Magalhaes SM; Pinheiro RF
    Haematologica; 2012 Oct; 97(10):e37-9; author reply e40. PubMed ID: 23053671
    [No Abstract]   [Full Text] [Related]  

  • 3. Expression of the anti-apoptotic gene survivin in myelodysplastic syndrome.
    Badran A; Yoshida A; Wano Y; Mutoh M; Imamura S; Yamashita T; Tsutani H; Inuzuka M; Ueda T
    Int J Oncol; 2003 Jan; 22(1):59-64. PubMed ID: 12469185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia.
    Ye D; Garcia-Manero G; Kantarjian HM; Xiao L; Vadhan-Raj S; Fernandez MH; Nguyen MH; Medeiros LJ; Bueso-Ramos CE
    J Hematop; 2009 Mar; 2(1):2-8. PubMed ID: 19669217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.
    Jiang Y; Dunbar A; Gondek LP; Mohan S; Rataul M; O'Keefe C; Sekeres M; Saunthararajah Y; Maciejewski JP
    Blood; 2009 Feb; 113(6):1315-25. PubMed ID: 18832655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survivin expression in "low-risk" and "high-risk" myelodysplastic syndromes.
    Gianelli U; Fracchiolla NS; Cortelezzi A; Pellegrini C; Savi F; Moro A; Grimoldi MG; Deliliers GL; Coggi G; Bosari S
    Ann Hematol; 2007 Mar; 86(3):185-9. PubMed ID: 17124585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptotic cells and clonally expanded cytotoxic T cells in bone marrow trephines of patients with myelodysplastic syndrome.
    Pülhorn H; Herrmann M; Harms H; Jung A; Baumann I
    Histopathology; 2012 Aug; 61(2):200-11. PubMed ID: 22690734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelodysplastic syndrome that progressed to acute myelomonocytic leukemia with eosinophilia showing peculiar chromosomal abnormality: a case report.
    Kim SH; Suh C; Choi SJ; Kim JG; Lee JH; Kim SB; Kim SW; Lee KH; Lee JS; Kim WK; Kim SH; Seo EJ; Chi HS
    J Korean Med Sci; 1999 Aug; 14(4):448-50. PubMed ID: 10485627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy-related myeloid neoplasms following treatment with radioiodine.
    Schroeder T; Kuendgen A; Kayser S; Kröger N; Braulke F; Platzbecker U; Klärner V; Zohren F; Haase D; Stadler M; Schlenk R; Czibere AG; Bruns I; Fenk R; Gattermann N; Haas R; Kobbe G; Germing U
    Haematologica; 2012 Feb; 97(2):206-12. PubMed ID: 21993688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The myelodysplastic syndromes. Part I. What are they? Part II. Classification.
    Galton DA
    Scand J Haematol Suppl; 1986; 45():11-20. PubMed ID: 3515515
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of microRNA-29b in myelodysplastic syndromes during transformation to overt leukaemia.
    Kirimura S; Kurata M; Nakagawa Y; Onishi I; Abe-Suzuki S; Abe S; Yamamoto K; Kitagawa M
    Pathology; 2016 Apr; 48(3):233-41. PubMed ID: 27020498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic syndromes: natural history and features of prognostic importance.
    Mufti GJ; Galton DA
    Clin Haematol; 1986 Nov; 15(4):953-71. PubMed ID: 3552350
    [No Abstract]   [Full Text] [Related]  

  • 13. Impaired mitochondrial gene transcription in myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes.
    Schildgen V; Wulfert M; Gattermann N
    Exp Hematol; 2011 Jun; 39(6):666-675.e1. PubMed ID: 21447369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells.
    Bacher U; Haferlach C; Alpermann T; Kern W; Schnittger S; Haferlach T
    Haematologica; 2011 Sep; 96(9):1284-92. PubMed ID: 21606170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome.
    Cleven AH; Nardi V; Ok CY; Goswami M; Dal Cin P; Zheng Z; Iafrate AJ; Abdul Hamid MA; Wang SA; Hasserjian RP
    Mod Pathol; 2015 Apr; 28(4):552-63. PubMed ID: 25412846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic importance of Aurora Kinases and mitotic spindle genes transcript levels in Myelodysplastic syndrome.
    Borges DP; Dos Santos AWA; Paier CRK; Ribeiro HL; Costa MB; Farias IR; de Oliveira RTG; França IGDF; Cavalcante GM; Magalhães SMM; Pinheiro RF
    Leuk Res; 2018 Jan; 64():61-70. PubMed ID: 29220700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
    Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS.
    Parker JE; Mufti GJ; Rasool F; Mijovic A; Devereux S; Pagliuca A
    Blood; 2000 Dec; 96(12):3932-8. PubMed ID: 11090080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome.
    Suciu S; Kuse R; Weh HJ; Hossfeld DK
    Cancer Genet Cytogenet; 1990 Jan; 44(1):15-26. PubMed ID: 2293879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.
    Xu F; Liu L; Chang CK; He Q; Wu LY; Zhang Z; Shi WH; Guo J; Zhu Y; Zhao YS; Gu SC; Fei CM; Li X
    Oncotarget; 2016 Feb; 7(7):8119-30. PubMed ID: 26812882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.